KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to -$327.8 million.

  • Jazz Pharmaceuticals' Cash from Investing Activities fell 253.12% to -$327.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 524.58%. This contributed to the annual value of -$508.2 million for FY2024, which is 211.66% down from last year.
  • Jazz Pharmaceuticals' Cash from Investing Activities amounted to -$327.8 million in Q3 2025, which was up 48.86% from -$641.0 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Cash from Investing Activities registered a high of $737.1 million during Q1 2021, and its lowest value of -$5.9 billion during Q2 2021.
  • For the 3-year period, Jazz Pharmaceuticals' Cash from Investing Activities averaged around -$164.5 million, with its median value being -$174.3 million (2023).
  • In the last 5 years, Jazz Pharmaceuticals' Cash from Investing Activities surged by 1,326.92% in 2021 and then plummeted by 5,538.82% in 2024.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Cash from Investing Activities stood at -$10.1 million in 2021, then crashed by 3,114.21% to -$324.4 million in 2022, then soared by 131.38% to $101.8 million in 2023, then crashed by 289.87% to -$193.3 million in 2024, then tumbled by 253.12% to -$327.8 million in 2025.
  • Its Cash from Investing Activities was -$327.8 million in Q3 2025, compared to -$641.0 million in Q2 2025 and -$168.9 million in Q1 2025.